GBA1 and Parkinson disease: The finding that Parkinson’s disease with GBA mutations is associated with reductions in glucosylceramidase activity in substantia nigra suggests that augmenting glucosylceramidase activity may be a valid therapeutic approach to reverse the biochemical consequences of the GBA mutation.